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Abstract: Integrated stress responses (ISR) may lead to cell death and tissue degeneration via
eukaryotic translation initiation factor 2 α (eIF2α)-mediated signaling. Alleviating ISR by modulating
eIF2α phosphorylation can reduce the symptoms associated with various diseases. Guanabenz
is known to elevate the phosphorylation level of eIF2α and reduce pro-inflammatory responses.
However, the mechanism of its action is not well understood. In this study, we investigated
the signaling pathway through which guanabenz induces anti-inflammatory effects in immune
cells, in particular macrophages. Genome-wide mRNA profiling followed by principal component
analysis predicted that colony stimulating factor 2 (Csf2, or GM-CSF as granulocyte macrophage
colony stimulating factor) is involved in the responses to guanabenz. A partial silencing of
Csf2 or eIF2α by RNA interference revealed that Interleukin-6 (IL6), Csf2, and Cyclooxygenase-2
(Cox2) are downregulated by guanabenz-driven phosphorylation of eIF2α. Although expression of
IL1β and Tumor Necrosis Factor-α (TNFα) was suppressed by guanabenz, their downregulation
was not directly mediated by eIF2α signaling. Collectively, the result herein indicates that
anti-inflammatory effects by guanabenz are mediated by not only eIF2α-dependent but also
eIF2α-independent signaling.
Keywords: guanabenz; microarray; inflammation; Csf2 (GM-CSF); eIF2α signaling
1. Introduction
Varying cellular stresses such as oxidation, nutrient deprivation, and stress to the endoplasmic
reticulum induce integrated stress responses (ISR), in which cells attempt to withstand adverse
environments in part by reducing the rate of protein synthesis [1]. Phosphorylated eukaryotic
translation initiation factor 2 α (eIF2α) contributes to lowering protein production, and chemical
compounds that block de-phosphorylation of eIF2α are known to suppress the cell death associated
with ISR [2]. Two such agents, salubrinal (479.8 Da) and guanabenz (231.1 Da), bind to a subunit
of protein phosphate 1 (PP1) complex and elevate the level of eIF2α phosphorylation [3,4]. We
have previously shown that both salubrinal and guanabenz activate bone-forming osteoblasts via
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eIF2α-mediated upregulation of activating transcription factor 4 (ATF4), one of the three known
transcription factors for bone formation [5]. Furthermore, they inhibit development of bone-resorbing
osteoclasts by inactivating nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), a master
transcription factor of osteoclastogenesis [5–7].
In spite of the functional commonality of salubrinal and guanabenz in skeletal tissues, their
chemical structures are dissimilar and their effects on inflammatory responses are largely different [8].
For instance, salubrinal downregulates the expression and activity of matrix metalloproteinase 13
(MMP13) in chondrocytes, and this downregulation is mediated via p38 and NFκB signaling [9].
Interestingly, salubrinal-driven regulation of p38 and NFκB is not linked to the phosphorylation level
of eIF2α, and guanabenz does not present an inhibitory effect to MMP13 [10]. Besides acting as an
inhibitor of PP1 complex, guanabenz serves as an agonist of α2 adrenergic receptor, and it has been
FDA-approved for treatment of hypertension [11]. However, salubrinal does not have any known link
to adrenergic signaling.
Recently guanabenz has been reported to have a potential therapeutic effect for multiple sclerosis,
which is an inflammatory disease associated with oligodendrocyte death in the central nervous
system [12]. It is proposed that enhancement of ISR activity by guanabenz contributes to damping
inflammatory responses and protecting cytokine-mediated cell death [12,13]. The study herein
aimed to understand the regulatory mechanism of anti-inflammatory actions by guanabenz in the
immune cells, in particular macrophages, paying attention to eIF2α-dependent and eIF2α-independent
signaling pathways.
In this study, we conducted in vitro analysis using four sources of immune cells (RAW264.7
macrophages, primary macrophages, Jurkat T lymphocytes, and HMC-1.1 mast cells). The effects of
guanabenz on inflammatory responses were evaluated through genome-wide microarray experiments
followed by a principal component analysis (PCA) [14]. PCA highlighted a set of genes that
were most significantly affected by administration of guanabenz, including early growth response
protein 2 (Egr2) [15] and colony-stimulating factor 2 (Csf2; also known as granulocyte macrophage
colony-stimulating factor, GM-CSF) [16]. We employed RNA interference as well as salubrinal
(inhibitor of de-phosphorylation of eIF2α), and searched potential regulatory pathways involved
in guanabenz-driven anti-inflammatory responses.
2. Results
2.1. Guanabenz-Driven Suppression of Inflammatory Gene Expression
Lipopolysaccharide (LPS)-stimulated RAW264.7 cells and mouse primary macrophages elevated
the mRNA levels of IL1β, IL6, TNFα, and Cox2, but their elevation was significantly reduced by
administration of 10 µM guanabenz for 6 h (Figure 1A,B). The mRNA levels of IL2 and IFNγ were
increased in phorbol myristate acetate (PMA)-stimulated Jurkat cells, while those of TNFα and IL13
were upregulated in PMA-stimulated HMC1.1 cells. However, administration of 5 or 10 µM guanabenz
significantly suppressed the upregulated mRNA levels (Figure 1C,D).
2.2. Prediction of the Pathways and Genes Involved in the Responses to Guanabenz
Genome-wide mRNA expression analysis predicted signaling pathways that were potentially
involved in the responses to guanabenz for 6 h in LPS-stimulated macrophages (Table 1). Those
pathways included inflammation-related pathways such as cytokine and chemokine signaling, and
rheumatoid arthritis, as well as macrophage-linked pathways such as T-cell receptor signaling and
hematopoietic cell lineage.
Int. J. Mol. Sci. 2016, 17, 674 3 of 12
Int. J. Mol. Sci. 2016, 17, 674 3 of 12 
 
 
Figure 1. Guanabenz-driven suppression of inflammatory gene expression. The single and double 
asterisks indicate p < 0.05 and p < 0.01, respectively. (A) Levels of IL1β, IL6, TNFα, and Cox2 mRNAs 
in LPS-stimulated RAW264.7 cells in response to 10 µM guanabenz; (B) levels of IL1β, IL6, TNFα, and 
Cox2 mRNAs in LPS-stimulated primary macrophages in response to 10 µM guanabenz; (C) levels of 
IL2 and IFNγ mRNAs in PMA-stimulated Jurkat cells in response to 5 and 10 µM guanabenz; (D) 
levels of TNFα and IL13 mRNAs in PMA-stimulated HMC1.1 cells in response to 10 µM guanabenz. 
Table 1. Microarray-based prediction of pathways. Selected Kyoto Encyclopedia of Genes and 
Genomics (KEGG) pathways for primary macrophages. 
Pathway Ratio p
Lysosome 3.27 0.0007 
T cell receptor signaling pathway 3.29 0.0011 
Hematopoietic cell lineage 3.70 0.0011 
Cytokine-cytokine receptor interaction 2.38 0.0011 
Fc gamma R-mediated phagocytosis 3.39 0.0017 
Rheumatoid arthritis 3.39 0.0026 
Chemokine signaling pathway 2.42 0.0044 
MAPK signaling pathway 2.06 0.0077 
ErbB signaling pathway 2.84 0.0154 
NOD-like receptor signaling pathway 3.45 0.0154 
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LPS, LPS and guanabenz) were separated as three distinctive clusters, in which the LPS + guanabenz 
B
re
la
tiv
e 
m
R
N
A
ab
un
da
nc
e
(x 103) (x 10
3)
C D
PMA+iono:    - +      +         
2
4
0
IFN-γ6
**
- +    +     +
- - 5    10  
**
(x 103)
- +       +         
0.5
1.0
0
IL13
1.5
*
2.0
- - 10  
(x 103)
5
10
0
IL215
**
PMA+iono: - +      +       +
Gu(μM):   - - 5     10  
**
re
la
tiv
e 
m
R
N
A
ab
un
da
nc
e
(x 103)
5
10
0
TNFα
15
**
20
Gu(μM):    - - 10  
re
la
tiv
e 
m
R
N
A
ab
un
da
nc
e
(x 103)
A
re
la
tiv
e 
m
R
N
A
ab
un
da
nc
e
0
LPS:       - +          +
IL1β20
10
*  15
Gu:        - - +  
5
5
10
0
IL615
**
LPS:        - +          +
Gu:        - - +  
20
0
LPS:       - +          +
40 **  
Gu:       - - +  
60 Cox2TNFα30
0
10
20
LPS:       - +           +
Gu:       - - +  
**  
(x 103) (x 103)
0
2
4
6
8
LPS:       - +          +
Gu:       - - +  
IL1β
0
10
20
30
40
LPS:       - +          +
Gu:       - - +  
IL6
*  **
0
200
400
600
800
LPS:       - +         +
Gu:       - - +  
*  
Cox2
0
10
20
30
40
LPS:       - +          +
Gu:       - - +  
TNFα
*  
Figure 1. uanabenz-driven suppre sion of infla atory gene expression. The single and double
asterisks indicate p < 0.05 and p < 0.01, respectively. (A) Levels of IL1β, IL6, TNFα, and Cox2 RNAs
in LPS-sti ulated R . ll i r t ) l l f I , IL6, T Fα, and
Cox2 R As in LPS-sti ulated pri ary acrophages in response to 10 µ guanabenz; (C) levels of
IL2 and IFNγ mRNAs in PMA-stimulated Jurkat cells in response to 5 and 10 µM gua abenz;
(D) levels of TNFα and IL13 mRNAs in PMA-stimulated HMC1.1 cells in response to 10 µM guanabenz.
T l icroa ray-based prediction of t ays. Selected Kyoto Encyclopedia of Genes and
Geno ics (KE ) path ays for pri ary acr a es.
Pathway Ratio p
Lysosome 3.27 0.0007
T cell receptor signaling pathway 3.29 0.0011
Hematopoietic cell lineage 3.70 0.0011
Cytokine-cytokine receptor interaction 2.38 0.0011
Fc gamma R-mediated phagocytosis 3.39 0.0017
Rheumatoid arthritis 3.39 0.0026
Chemokine signaling pathway 2.42 0.0044
MAPK signaling pathway 2.06 0.0077
ErbB signaling pathway 2.84 0.0154
NOD-like receptor signaling pathway 3.45 0.0154
In the primary and secondary principal axes in the sample plane, the sample groups (control, LPS,
LPS and guanabenz) were separated as three distinctive clusters, in which the LPS + guanabenz group
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(Gua) partially restored the negative effect of the LPS group along the first principal axis (Figure 2A).
In the corresponding gene plane, the genes with the most negative values in the first principal axis
are highlighted (Figure 2B). Among these genes, we focused on Egr2 and Csf2 (GM-CSF) since their
LPS-driven upregulation was significantly downregulated by guanabenz (Table 2).
Table 2. Heat map of the genes highlighted in Figure 2B.
Gene Description p1 C1 C2 C3 L1 L2 L3 G1 G2 G3
F3 coagulation factor III ´0.997
Has1 hyaluronan synthase1 ´0.992
Il12a interleukin 12a ´0.979
Egr2 early growth response 2 ´0.967
Csf2 colony stimulating factor 2 ´0.964
Serpinb2 serine/cysteine peptidase inhibitor, B2 ´0.946
Slc20a1 solute carrier family 20, member 1 ´0.317
C1–C3, control samples; L1–L3, LPS samples; and G1–G3, Guanabenz-treated LPS samples. The blue and red
colors indicate the downregulation and upreguation, respectively.
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LPS and 10 µM guanabenz, guanabenz suppressed Csf2 mRNA levels to 59% (RAW cells) and 18% 
(primary macrophages), and Egr2 mRNA level to 77% (RAW cells) and 37% (primary macrophages). 
In RAW264.7 cells, the LPS-induced level of Csf2 protein was significantly reduced by 6 h 
incubation with 10 µM guanabenz (Figure 4A). The LPS-induced protein level of Egr2 was 
significantly reduced not by 10 but by 20 µM guanabenz (Figure 4B). In primary macrophages, 
however, 10 µM guanabenz was sufficient to suppress LPS-induced elevation of Egr2 protein at 6 h 
(Figure 4C,D). 
Figure 2. Mic o rray-based prediction of reg l genes in response to guanabenz. (A) separation
of three groups (control, LPS, and LPS + guan ) n the first and second principal lane (sample
plane); (B) locations of the genes significantly altered by LPS and guanabenz on the first and second
principal plane (gene plane). The genes marked in red were upregulated by LPS, and significantly
downregulated by guanabenz.
2.3. Guanabenz-Driven Downregulation of Egr2 and Csf2 in Lipopolysaccharide (LPS)-Stimulated Cells
PCA prediction indicated potential involvement of Egr2 and Csf2 in guanabenz-driven
suppression of pro-inflammatory genes. Examination of their mRNA levels in the presence and
absence of 5 or 10 µM guanabenz for 6 h revealed that guanabenz significantly reduced the mRNA
levels of Egr2 and Csf2 in LPS-stimulated RAW264.7 cells (Figure 3A,B). In response to 0.1 µg/mL
LPS and 10 µM guanabenz, guanabenz suppressed Csf2 mRNA levels to 59% (RAW cells) and 18%
(primary macrophages), and Egr2 mRNA level to 77% (RAW cells) and 37% (primary macrophages).
In RAW264.7 cells, the LPS-induced level of Csf2 protein was significantly reduced by 6 h
incubation with 10 µM guanabenz (Figure 4A). The LPS-induced protein level of Egr2 was significantly
reduced not by 10 but by 20 µM guanabenz (Figure 4B). In primary macrophages, however, 10 µM
guanabenz was sufficient to suppress LPS-induced elevation of Egr2 protein at 6 h (Figure 4C,D).
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Figure 4. Alterations in the levels of Egr2 protein and Csf2 protein in response to guanabenz. The
single asterisk indicates p < 0.05. (A,B) Egr2 and Csf2 protein levels in LPS-stimulated RAW264.7 cells
in response to 10 and 20 µM guanabenz for 6 h, respectively; (C,D) Egr2 and Csf2 protein levels in
LPS-stimulated primary macrophages in response to 10 µM guanabenz for 4 and 6 h.
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2.4. Potential Linkage of Egr2 and Csf2 to IL1β, TNFα, and Cox2
To examine the role of Egr2 and Csf2 in pro-inflammatory gene expression, their partial silencing
was conducted using siRNAs in RAW264.7 cells. In response to Egr2 siRNA (Figure 5A,B), the mRNA
levels of IL1β and TNFα were reduced and the mRNA level of Csf2 was elevated (Figure 5C). In
response to Csf2 siRNA (Figure 6A,B), the Cox2 mRNA level was downregulated and the level of Egr2
mRNA was upregulated (Figure 6C). Neither siRNA altered the mRNA level of eIF2α.
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Figure 6. Effects of a partial silencing of Csf2 on the mRNA levels of the selected genes in
LPS-stimulated RAW264.7 cells. The single and double asterisk indicates p < 0.05 and p < 0.01,
respectively. (A,B) Reduction of Csf2 by treatment with Csf2 siRNA; (C) levels of IL1β, IL6, TNFα,
Cox2, eIF2α, and Egr2 mRNAs in response to Csf2 siRNA treatment in LPS-stimulated RAW264.7 cells.
2.5. Direct Linkage of eif2α Signaling to IL6, Cox2, and Csf2
To evaluate the role of eIF2α signaling in the response to guanabenz, the protein level of eIF2α
was reduced by RNA interference (Figure 7A–C). This partial silencing of eIF2α decreased not only the
level of eIF2α but the level of phosphorylated eIF2α. The PCR results revealed that the mRNA levels
of IL6 and Cox2, as well as Csf2, were significantly elevated by eIF2α siRNA (Figure 7D). However,
the level of Egr2 mRNA was unchanged and a slight reduction in TNFα mRNA level was detected.
In response to 5 or 10 µM salubrinal, LPS-driven upregulation of IL1β, IL6, TNFα, Cox2, and Csf2
mRNAs was significantly reduced (Figure 8A). Unlike the response to guanabenz, however, the level
of Egr2 mRNA was further elevated by administration of 5 or 10 µM salubrinal.
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RAW264.7 cells.
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suppression of Cox2. Recently, Csf2 has been revealed as a potential therapeutic target in rheumatoid
arthritis as well as multiple sclerosis, an inflammatory demyelinating disease in the central nervous
system. A high level of Csf2 is detected in joints with rheumatoid arthritis [13], while an increase in
Csf2-expressing B cells is detected in patients with multiple sclerosis [16]. Consistent with the results
of this study, administration of guanabenz is reported to protect the nerve cells and alleviate clinical
symptoms in a mouse model of multiple sclerosis [12].
While guanabenz and salubrinal are capable of suppressing LPS-driven upregulation of IL1β
and TNFα, a partial silencing of eIF2α does not confirm that the effects of guanabenz are always
mediated via eIF2α signaling. Guanabenz is known as an inhibitor of α2 adrenergic signaling [11], but
treatment with clonidine, another α2 adrenergic agonist, did not alter expression of IL1β or TNFα (data
not shown). We observed that Egr2 mRNA level was reduced by guanabenz and not by salubrinal.
We also observed that a partial silencing of Egr2 by RNA interference significantly decreased the
mRNA levels of IL1β and TNFα. Thus, it is possible that eIF2α-independent anti-inflammatory
responses by guanabenz are mediated by Egr2. Egr2 is a transcription factor, and its mutation causes
musculoskeletal diseases such as Charcot-Marie-Tooth disease and Dejerine–Sottas disease. It promotes
the proliferation and survival of osteoprogenitor cells and maintains bone architecture [20]. However,
its role in inflammation has not been well understood. In osteoblasts, expression of Egr2 is suppressed
by glucocorticoids that are often administered for the management of autoimmune and inflammatory
diseases [21]. Although both guanabenz and salubrinal elevate the level of eIF2α phosphorylation,
they inhibit eIF2α’s phosphatase by binding to different subunits, and their potential link to Egr2
appears to differ.
Signaling pathways are dynamically regulated in time and space. In this study, we specifically
analyzed the role of Csf2 and Egr2 from the list of seven genes in Table 2 since they are a cytokine
and transcription factor, respectively. It is possible that other genes are also involved in the responses
to guanabenz. To understand the complex signaling machinery, it is recommended to evaluate the
interactive signaling in Figure 8 in a dynamical fashion using a range of guanabenz dosages. Although
our microarray analysis and in vitro experiments were mostly conducted 6 h after incubation with
guanabenz, gene expression at earlier or later time points may present other regulatory candidates. We
have observed differential responses of Csf2 and Egr2 in RAW264.7 cells and primary macrophages.
Further analysis is recommended to evaluate a potential cause of the observed variations, such as
cellular differentiation stages and responsiveness to LPS, as well as the mechanism of the action of
guanabenz in other immune cells.
4. Experimental Section
4.1. Cell Culture
RAW264.7 macrophages [22] and primary macrophages were cultured in αMEM with 10% FBS
and antibiotics. Mouse bone marrow cells were grown with 10 ng/mL macrophage colony-stimulating
factor (M-CSF, PeproTech, Rocky Hills, NC, USA) for three days, and the surface-attached cells were
used as primary macrophages. Jurkat T lymphocytes [23] and HMC-1.1 mast cells [24] were cultured
in RPMI 1640 and IMDM with 1-thioglycerol, respectively. RAW264.7 cells and primary macrophages
were activated by 0.1 or 1 µg/mL lipopolysaccharide (LPS), while Jurkat cells and HMC-1.1 cells were
activated by 100 nM phorbol myristate acetate (PMA) and 1 µM ionomycin. Of note, the MTT assay
using RAW264.7 cells for evaluating cytotoxicity revealed that administration of guanabenz at 5, 10,
and 20 µM for two days reduced relative cell growth down to 87%, 86%, and 75% of the control cells
without guanabenz administration.
4.2. Microarray
Genome-wide expression analysis was conducted using RNA isolated from mouse primary
macrophages (Mouse Gene 2.0 ST arrays, Affymetrix, Cleveland, OH, USA). The three groups
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(three samples per group) were “CN” (control), “LPS” (0.1 µg/mL LPS), and “Gua” (0.1 µg/mL LPS
and 10 µM guanabenz). The samples were harvested 6 h after treatment with LPS and/or guanabenz.
First, genes that were significantly modulated by LPS as well as guanabenz were identified. Then,
signaling pathways that were over-represented in the selected genes were identified using WebGestalt
software. Principal component analysis (PCA) was also performed, and genes that were likely to
be involved in the responses to LPS and guanabenz were predicted. In brief, nine samples in three
groups were positioned in the plane of the first and second principal axes, in which the first principal
axis was identified as the axis for anti-inflammatory responses. Then, the genes whose mRNA levels
were significantly altered along the first principal (anti-inflammatory) axis were selected for further
in vitro evaluation.
4.3. qPCR and Western Blot Analysis
Reverse transcription was conducted using total RNA and a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Carlsbad, CA, USA). Quantitative real-time PCR was performed
using Power SYBR green PCR master mix kits (Applied Biosystems). Using the PCR primers (Table 3),
the mRNA levels of inflammatory genes (IL1β, IL2, IL6, IL13, TNFα, IFNγ, Cox2) as well as regulatory
genes (eIF2α, Csf2, and Egr2) were determined with glyceraldehyde-3-phosphatedehydrogenase
(GAPDH) as an internal control. Western blot analysis was conducted using 10%–12% sodium dodecyl
sulfate (SDS) gels and polyvinylidene difluoride (PVDF) transfer membranes (Millipore, Billerica,
MA, USA). Protein samples were isolated using a RIPA buffer. We used primary antibodies specific
to Csf2 (Abcam, Cambridge, MA, USA), Egr2 (Proteintech, Rosemont, IL, USA), eIF2α and p-eIF2α
(Cell Signaling, Danvers, MA, USA) as well as a secondary antibody conjugated with horseradish
peroxidase (Cell Signaling). The level of proteins was detected using a SuperSignal west femto
maximum sensitivity substrate (Thermo Scientific, Waltham, MA, USA), and the level of β-actin
(Sigma, St. Louis, MO, USA) was employed as a control.
Table 3. Real-time polymerase chain reaction (PCR) primers and siRNAs used in this study.
Gene Accession Number Forward Primer Backward Primer
Mouse Primers
IL1β NM_008361 51-GCCCATCCTCTGTGACTCAT-31 51-AGGCCACAGGTATTTTGTCG-31
IL6 NM_031168 51-TTCCATCCAGTTGCCTTCTT-31 51-TCCACGATTTCCCAGAGAAC-31
TNFα NM_013693 51-GAACTGGCAGAAGAGGCACT-31 51-AGGGTCTGGGCCATAGAACT-31
Cox2 AF378830 51-CCCCCACAGTCAAAGACACT-31 51-CTCATCACCCCACTCAGGAT-31
Csf2 NM_009969 51-GAGGCCATCAAAGAAGCCCT-31 51-AAATTGCCCCGTAGACCCTG-31
eIF2α NM_026114 51-GAATGTACTCCAGATTGGCTGACTAC-31 51-CCTCAATGTGAAGACCTGTATCGA-31
Egr2 NM_010118 51-GATCTGCATGCGAAACTTCA-31 51-CACTGCTCTTCCGTTCCTTC-31
GAPDH NM_008084 51-TGCACCACCAACTGCTTAG-31 51-GGATGCAGGGATGATGTTC-31
Human Primers
IFNγ NM_000619 51-TTCAGCTCTGCATCGTTTTG-31 51-TCTTTTGGATGCTCTGGTCA-31
IL2 NM_000586 51-GCAACTCCTGTCTTGCATTG-31 51-GCCTTCTTGGGCATGTAAAA-31
IL13 NM_002188 51-GTACTGTGCAGCCCTGGAAT-31 51-TTTACAAACTGGGCCACCTC-31
TNFα NM_000594 51-CAGAGGGCCTGTACCTCATC-31 51-GGAAGACCCCTCCCAGATAG-31
GAPDH NM_001289745 51-GCACCGTCAAGGCTGAGAAC-31 51-ATGGTGGTGAAGACGCCAGT-31
Mouse siRNAs
Csf2 (GM-CSF) 5
1-GCGGAAGACAAACGAGAGA-31 51-GCCUGAAGAUAUUCGAGCA-31
51-AUGAAGAGGUAGAAGUCGU-31 51-CCAGCUACUACCAGACAUA-31
eIF2α (eIF2s1) 5
1-UCGAGCAGAUAUUGAAGUA-31 51-CAUGAUUCUUCUUAGUGAA-31
51-UGUCACAAGUUAAAGCCAA-31 51-GAACUCAAUGGGCAAGUAA-31
Egr2 51-CGACCUCGAAAGUACCCUA-31
Control #1 (NC1) for Egr2 51-UGUACUGCUUACGAUUCGG-31
Control #2 (NC2) for Csf2 & eIF2α 5
1-UGGUUUACAUGUCGACUAA-31 51-UGGUUUACAUGUUGUGUGA-31
51-UGGUUUACAUGUUUUCUGA-31 51-UGGUUUACAUGUUUUCCUA-31
4.4. RNA Silencing Using siRNAs
RAW264.7 cells were transiently transfected with siRNA specific to Egr2, non-specific control
siRNA #1 (Life Technologies, Grand Island, NY, USA), Csf2, eIF2α, or non-specific control siRNA
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#2 (GE Dharmacon, Lafayette, CO, USA) (Table 3), in Opti-MEM I medium using Lipofectamine
RNAiMAX (Life Technologies). The efficiency of silencing was assessed by Western blotting 48 h
after transfection.
4.5. Statistical Analysis
Three to four independent experiments were conducted, and data were expressed as mean ˘ S.D.
Statistical significance was evaluated using Student’s t-test at p < 0.05; the single and double asterisks
indicate p < 0.05 and p < 0.01, respectively.
5. Conclusions
This study demonstrates that administration of guanabenz reduces expression of Egr2 and Csf2
as well as inflammatory genes such as IL1β, IL6, TNFα, and Cox2 in macrophages in eIF2α-dependent
and eIF2α-independent signaling.
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